Compare WLKP & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLKP | DNA |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.0M | 562.3M |
| IPO Year | 2014 | N/A |
| Metric | WLKP | DNA |
|---|---|---|
| Price | $18.96 | $8.84 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 88.3K | ★ 1.2M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $1,133,706,000.00 | $180,606,000.00 |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $13.98 | $14.41 |
| P/E Ratio | $13.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.75 | $5.00 |
| 52 Week High | $25.04 | $17.58 |
| Indicator | WLKP | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 42.69 |
| Support Level | $18.75 | $8.56 |
| Resistance Level | $19.26 | $9.38 |
| Average True Range (ATR) | 0.42 | 0.49 |
| MACD | 0.17 | 0.22 |
| Stochastic Oscillator | 89.70 | 78.71 |
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.